DK193588A - Anvendelser af dopaminagonister - Google Patents

Anvendelser af dopaminagonister

Info

Publication number
DK193588A
DK193588A DK193588A DK193588A DK193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A
Authority
DK
Denmark
Prior art keywords
dopaminagonists
applications
Prior art date
Application number
DK193588A
Other languages
Danish (da)
English (en)
Other versions
DK193588D0 (da
Inventor
Rudolf Markstein
Jose Palacios
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878708626A external-priority patent/GB8708626D0/en
Priority claimed from GB878708898A external-priority patent/GB8708898D0/en
Priority claimed from GB878710062A external-priority patent/GB8710062D0/en
Priority claimed from GB878720366A external-priority patent/GB8720366D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of DK193588D0 publication Critical patent/DK193588D0/da
Publication of DK193588A publication Critical patent/DK193588A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK193588A 1987-04-10 1988-04-08 Anvendelser af dopaminagonister DK193588A (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878708626A GB8708626D0 (en) 1987-04-10 1987-04-10 Indolophenanthridines
GB878708898A GB8708898D0 (en) 1987-04-14 1987-04-14 Indolophenanthridines
GB878710062A GB8710062D0 (en) 1987-04-28 1987-04-28 Indolophenanthridines
GB878720366A GB8720366D0 (en) 1987-08-28 1987-08-28 Dopamine d1 receptor agonists

Publications (2)

Publication Number Publication Date
DK193588D0 DK193588D0 (da) 1988-04-08
DK193588A true DK193588A (da) 1988-10-11

Family

ID=27449909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK193588A DK193588A (da) 1987-04-10 1988-04-08 Anvendelser af dopaminagonister

Country Status (11)

Country Link
US (1) US4855306A ( )
JP (1) JPS63258819A ( )
KR (1) KR880012227A ( )
AU (1) AU1440088A ( )
DE (1) DE3811274A1 ( )
DK (1) DK193588A ( )
FR (1) FR2613623A1 ( )
GB (1) GB2205495A ( )
IT (1) IT1219906B ( )
NL (1) NL8800823A ( )
SE (1) SE8801275L ( )

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
WO2005110405A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20080306019A1 (en) * 2005-05-03 2008-12-11 Booze Rosemarie M Dopamine Receptor Agonists in the Treatment and Prevention of Hiv-Induced Dementia
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TWI504419B (zh) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2750903C (en) * 2009-08-27 2015-08-11 Daikin Industries, Ltd. Processing additive, molding composition, masterbatch of processing additive and molding article
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
DK2858640T3 (da) 2012-06-06 2020-06-29 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402392A1 (de) * 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung

Also Published As

Publication number Publication date
KR880012227A (ko) 1988-11-26
US4855306A (en) 1989-08-08
SE8801275A0 (sv) 1988-10-19
NL8800823A (nl) 1988-11-01
AU1440088A (en) 1988-10-13
DK193588D0 (da) 1988-04-08
DE3811274A1 (de) 1988-10-27
IT8847814A0 (it) 1988-04-05
SE8801275D0 (sv) 1988-04-08
SE8801275L (sv) 1988-10-19
JPS63258819A (ja) 1988-10-26
GB8808125D0 (en) 1988-05-11
IT1219906B (it) 1990-05-24
GB2205495A (en) 1988-12-14
FR2613623A1 (fr) 1988-10-14

Similar Documents

Publication Publication Date Title
DK193588D0 (da) Anvendelser af dopaminagonister
DK208188D0 (da) Anvendelse af 17-ketosteroider
DK450189D0 (da) Strimmel af sammenfoejede soem
DK363887D0 (da) Anvendelse af bromcruptin
DK348385A (da) Anvendelse af cyclosporiner
DK662687D0 (da) Anvendelse af tricycliske carbazoloner
DK25389A (da) Tolkning af elektriske diagrafier
DK549688A (da) Fremstilling af peptider
DK185988D0 (da) Anvendelse af antigen
DK360484A (da) Modifikation af soja-isolat
DK38593D0 (da) Alkoxymethylethere af glyceroler
DK102389A (da) Anvendelse af interleukin
DK119688A (da) 23-oxo- (-keto-) og 23-imino-derivater af mono- og diepoxy-ll-f28249-forbindelser
DK316589D0 (da) Substituerede azacyclohexylderivater af rifamyciner
DK104489D0 (da) Anvendelse af triazolderivater
DK562289D0 (da) Anvendelse af somatostatiner
DK293787A (da) Ekspression af en amyloglucosidase
DK426089D0 (da) Omestring af phospholipider
DK541487D0 (da) Sammenfoejning af materialer
DK251788D0 (da) Stabile creatinamidinohydrolasemutanter
DK105089D0 (da) Fremstilling af bis(amin-holdige)benzendioler
DK487289D0 (da) Omestring af phospholipider
DK153045C (da) Sammenkobling af fortrinsvis langstrakte elementer
DK621088D0 (da) Theemballage af theposetypen
DK531987D0 (da) Oprensning af antistoffer

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment